Atrium Therapeutics Announces $50 Million Private Placement

Atrium Therapeutics, Inc. has entered into a private placement with institutional investors for approximately $50 million, to fund development of its product candidates and other corporate purposes.

Why it matters. The funds will support Atrium Therapeutics' research and development efforts, potentially accelerating the advancement of RNA therapeutics for cardiomyopathies.